Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 11/20 | 0.46 |
| ▸ | JAK2 | O60674 | 10/20 | 0.46 |
| ▸ | FLT3 | P36888 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | FGR | P09769 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | SIK1 | P57059 | 1/20 | 0.46 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | TSSK2 | Q96PF2 | 1/20 | 0.46 |
| ▸ | WNK3 | Q9BYP7 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027748 | 0.92 | KCNH2 (0.53) | KCNH2NTRK1JAK2FLT3FGFR1 | |
| SCHEMBL3022623 | 0.90 | KCNH2 (0.59) | KCNH2NTRK1JAK2FLT3FGFR1 | |
| SCHEMBL3026049 | 0.90 | KCNH2 (0.66) | KCNH2NTRK1JAK2FLT3FGFR1 | |
| SCHEMBL3029292 | 0.88 | NTRK1 (0.44) | KCNH2NTRK1JAK2FLT3FGFR1 | |
| SCHEMBL3123723 | 0.88 | KCNH2 (0.42) | KCNH2NTRK1JAK2FLT3FGFR1 | |
| SCHEMBL3123733 | 0.88 | KCNH2 (0.42) | KCNH2NTRK1JAK2FLT3FGFR1 | |
| SCHEMBL3020033 | 0.87 | JAK3 (0.57) | KCNH2NTRK1JAK2FLT3JAK3 | |
| SCHEMBL3011834 | 0.83 | NTRK1 (0.61) | KCNH2NTRK1JAK2JAK3IGF1R | |
| SCHEMBL3026832 | 0.81 | KCNH2 (0.68) | KCNH2NTRK1JAK2FLT3FGFR1 | |
| SCHEMBL3026499 | 0.80 | KCNH2 (0.74) | KCNH2NTRK1JAK2FLT3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ABL1, MCL1, ETV6 | KCNH2 2505/4885NTRK1 4243/4885JAK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.